Acta Scientific Pharmacology

Review Article Volume 1 Issue 10

Immunological Aspects of Cytokine Therapy, Signalling Pathway and its Molecular Mechanisms in the Fight Against SARS-CoV-2

Najib Lawan Yahaya1#, Mudassir Lawal1#, Abhishek Kumar Verma1*, Zaharaddeen Umar Naabba1#, Avinash Kumar2, Abhay Raj Kori3, Arundhiti Sharma4, Harpreet Kaur4, Dinesh Kumar Dhawan5 and Mayadhar Barik4*

1Department of Life Sciences, Faculty of Science and Technology, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
2Department of Paramedical Sciences, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
3Department of Biochemistry and Microbial Sciences, Central University of Punjab, Bathinda, Punjab, India
4Assistant Professor, Department of Life Sciences, School of Science and Technology, Mewar University, Gangrar, Chittorgarh, Rajasthan, India

*Corresponding Author: Dr. Mayadhar Barik, Chief Researcher Basic and Clinical Sciences Under Science and Technology Division and Associate Professor in Department of Biochemistry and HOD Paramedical Sciences at Mewar University, Chittorgarh, Rajasthan, India.

Received: July 25, 2020; Published: September 16, 2020

Reprints View PDF Related Articles

×

Abstract

  The COVID-19 is a pandemic caused by SARS-CoV -2 virus has presented a striking challenge into the health care systems (HCSs) around the World and currently is the source of public health concern globally. The treatment of this disease has remained challenging as there are no proven effective vaccines or therapeutic agents against the virus. Cytokine Storm Syndrome (CSS) is an unregulated inflammatory process response arising from immune effector cells (IECs) releasing proinflammatory cytokines. That occurs as a result of the overproduction of pro-inflammatory cytokines. CSS is a frequently occurring feature of severe infections with COVID-19 pneumonia and violent inflammatory immune response (VIIR) is stimulated by cytokine storm syndrome (CSS) is misleading into the development of symptoms such as fever, throat infections, headaches, dizziness, fatigue, cardiomyopathy, lung injury, acute respiratory distress, multiple organ failure, and subsequent death of the majority of the patients. The new therapeutic strategies under investigation are targeting to the overactive cytokine response (OCR) within the anti-cytokine therapies and immunosuppressive agents. CSS helps to down-regulate and dampen the aberrant pro-inflammatory response of the host and may bring an understanding and insights into the treatment of the SARS-CoV-2 virus. In this review, we have outlined and discussed the different types of cytokines therapies and their mechanism of actions. Currently, being explored and evaluated those that are not yet evaluated for their efficacy and safety in the treatment of COVID-19 and associated with the cytokine storm syndrome (CSS). We suggested that the clinical trials should be initiated for those are new therapies that are not yet explored to evaluate their efficacy and safety in the management and treatment of COVID-19 pneumonia and the SARS-CoV-2.

Keywords: Pediatric Dentistry; Oral Habits; Nursing Bottle Caries; Dental Trauma; Cleft Palate; Natal Teeth; Neonatal Teeth

×

References

  1. Lu R., et al. “Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding”. The Lancet10224 (2020): 565-574.
  2. Zhou P., et al. “A pneumonia outbreak associated with a new coronavirus of probable bat origin”. Nature7798 (2020): 270-273.
  3. Andersen KG., et al. “The proximal origin of SARS-CoV-2”. Nature Medicine4 (2020): 450-452.
  4. Brucková M., et al. “The Adaptation of Two Human Coronavirus Strains (OC38 and OC43) to Growth in Cell Monolayers”. Proceedings of the Society for Experimental Biology and Medicine2 (1970): 431-435.
  5. Hamre D., et al. “Growth and Intracellular Development of a New Respiratory Virus”. Journal of Virology4 (1967): 810-816.
  6. Woo P C Y., et al. “Characterization and Complete Genome Sequence of a Novel Coronavirus, Coronavirus HKU1, from Patients with Pneumonia”. Journal of Virology2 (2005): 884-895.
  7. Van Der Hoek L., et al. “Identification of a new human coronavirus”. Nature Medicine4 (2004): 368-373.
  8. Wang M., et al. “SARS-CoV infection in a restaurant from palm civet”. Emerging Infectious Diseases 12 (2005): 1860-1865.
  9. Holmes KV and Dominguez SR. “The new age of virus discovery: genomic analysis of a novel human betacoronavirus isolated from a fatal case of pneumonia”. MBio1 (2013): e00548-12.
  10. Wu R., et al. “An Update on Current Therapeutic Drugs Treating COVID-19” (2020).
  11. Liu C., et al. “Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases”. ACS Central Science3 (2020): 315-331.
  12. Ray A. “Cytokines and their Role in Health and Disease: A Brief Overview”. MOJ Immunology2 (2016).
  13. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. The Lancet10223 (2020): 497-506.
  14. Li X., et al. “Molecular immune pathogenesis and diagnosis of COVID-19”. Journal of Pharmaceutical Analysis2 (2020): 102-108.
  15. Diamanti AP., et al. “Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity”. International Journal of Molecular Sciences 9 (2020): 3330.
  16. Pillaiyar T., et al. “Recent discovery and development of inhibitors targeting coronaviruses”. Drug Discovery Today4 (2020): 668-688.
  17. Wang B X and Fish E N. “Global virus outbreaks: Interferons as 1st responders”. Seminars in Immunology 43 (2019a): 101300-101300.
  18. The Nile., et al. “COVID-19: Pathogenesis, cytokine storm, and therapeutic potential of interferons”. Cytokine and Growth Factor Reviews (2020).
  19. Li H., et al. “Coronavirus disease 2019 (COVID-19): current status and future perspectives”. International Journal of Antimicrobial Agents 5 (2020): 105951.
  20. Zou X., et al. “Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection”. Frontiers of Medicine2 (2020): 185-192.
  21. Simmons G., et al. “Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry”. Proceedings of the National Academy of Sciences of the United States of America 12 (2004): 4240-4245.
  22. Kuba K., et al. “Trilogy of ACE2: A peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters”. Pharmacology and Therapeutics1 (2010): 119-128.
  23. Perlman S and Netland J. “Coronaviruses post-SARS: Update on replication and pathogenesis”. Nature Reviews Microbiology 6 (2009): 439-450.
  24. Guan W., et al. “Clinical characteristics of coronavirus disease in 2019 in China”. New England Journal of Medicine18 (2020): 1708-1720.
  25. Hamming I., et al. “Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. The first step in understanding SARS pathogenesis”. Journal of Pathology2 (2004): 631-637.
  26. Yoshikawa T., et al. “Severe Acute Respiratory Syndrome (SARS) Coronavirus-Induced Lung Epithelial Cytokines Exacerbate SARS Pathogenesis by Modulating Intrinsic Functions of Monocyte-Derived Macrophages and Dendritic Cells”. Journal of Virology7 (2009): 3039-3048.
  27. Wu Z and McGoogan JM. “Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention”. JAMA - Journal of the American Medical Association13 (2020): 1239-1242.
  28. Mossel EC., et al. “SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells”. Virology1 (2008): 127-135.
  29. Lei J., et al. “CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia”. Radiology1 (2020): 18-18.
  30. Zhang W., et al. “The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China”. Clinical Immunology 214 (2020).
  31. Zumla A., et al. “Reducing mortality from 2019-nCoV: host-directed therapies should be an option”. The Lancet 10224 (2020): e35-e36.
  32. Guo J., et al. “The serum profile of hypercytokinemia factors identified in H7N9-infected patients can predict fatal outcomes”. Scientific Reports1 (2015): 1-10.
  33. Li X., et al. “Molecular immune pathogenesis and diagnosis of COVID-19”. Journal of Pharmaceutical Analysis2 (2020): 102-108.
  34. Teijaro J R., et al. “Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection”. Proceedings of the National Academy of Sciences of the United States of America10 (2014): 3799-3804.
  35. Xu Z., et al. “Pathological findings of COVID-19 associated with acute respiratory distress syndrome”. The Lancet Respiratory Medicine 4 (2020): 420-422.
  36. Rothan HA and Byrareddy SN. “The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak”. Journal of Autoimmunity 109 (2020a).
  37. Georgiev T. “Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs”. Rheumatology International5 (2020): 825-826.
  38. Sun X., et al. “Cytokine storm intervention in the early stages of COVID-19 pneumonia”. Cytokine and Growth Factor Reviews. Elsevier Ltd (2020).
  39. Wu JT., et al. “Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study”. The Lancet10225 (2020): 689-697.
  40. Bajema KL., et al. “Persons evaluated for 2019 novel coronavirus - United States, January 2020”. Morbidity and Mortality Weekly Report6 (2020): 166-170.
  41. SL K., et al. “Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients”. Virus Research2 (2020): 260-269.
  42. Masihi K N. “Progress on novel immunomodulatory agents for HIV-1 infection and other infectious diseases”. Expert Opinion on Therapeutic Patents6 (2003): 867-882.
  43. Foster G R. “Pegylated interferons for the treatment of chronic hepatitis C: Pharmacological and clinical differences between peginterferon-α-2a and peginterferon-α-2b”. Drugs2 (2020): 147-165.
  44. Liu X., et al. “Evaluation of plasma exchange and continuous veno-venous hemofiltration for the treatment of severe avian influenza A (H7N9): A cohort study”. Therapeutic Apheresis and Dialysis2 (2015): 178-184.
  45. Li C C., et al. “Repurposing host-based therapeutics to control coronavirus and influenza virus”. Drug Discovery Today3 (2019): 726-736.
  46. Tanaka T and Kishimoto T. “Targeting interleukin-6: All the way to treat autoimmune and inflammatory diseases”. International Journal of Biological Sciences9 (2012): 1227-1236.
  47. Choy E and Rose-John S. “Interleukin-6 as a Multifunctional Regulator: Inflammation, Immune Response, and Fibrosis”. Journal of Scleroderma and Related Disorders 2 (2017): S1-S5.
  48. Liu T., et al. “The potential role of IL-6 in monitoring severe case of coronavirus disease”. medRxiv (2019).
  49. Le R Q., et al. “FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome”. The Oncologist8 (2018): 943-947.
  50. Bjornsson A H., et al. “First case of COVID-19 treated with tocilizumab in Iceland”. Laeknabladid 5 (2020): 247-250.
  51. Xu X., et al. “Effective treatment of severe COVID-19 patients with tocilizumab”. PNAS20 (2020): 10970-10975.
  52. Liu B., et al. “Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?” Journal of Autoimmunity (2020).
  53. What is the role of the IL-6 inhibitor tocilizumab (Actemra) in the treatment of coronavirus disease 2019 (COVID-19)?.
  54. Huizinga T W J., et al. “Sarilumab, a fully human monoclonal antibody against IL-6R αin patients with rheumatoid arthritis and an inadequate response to methotrexate: Efficacy and safety results from the randomised SARIL-RA-MOBILITY part a trial”. Annals of the Rheumatic Diseases9 (2014): 1626-1634.
  55. Lee EB., et al. “Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis”. Clinical Pharmacokinetics6 (2017): 607-615.
  56. First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19. (2020).
  57. Study on the Use of Sarilumab in Patients With COVID-19 Infection - Full Text View - ClinicalTrials.gov. (2020).
  58. Sanofi US Media Room (2020).
  59. Zhang W., et al. “The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China”. Clinical Immunology 214 (2020).
  60. Mehta P., et al. “COVID-19: consider cytokine storm syndromes and immunosuppression”. The Lancet10229 (2020): 1033-1034.
  61. Ceribelli A., et al. “Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy”. Journal of Autoimmunity 109 (2020): 102442.
  62. Van Rhee F., et al. “Castleman Disease in the 21st Century: An Update on Diagnosis, Assessment, and Therapy”. Clinical Advances in Hematology and Oncology7 (2010).
  63. Gritti G., et al. “Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support”. MedRxiv (2020).
  64. Etti AE., et al. “Interleukin-1”. In eLS (2018): 1-9.
  65. Behrens E M and Koretzky G A. “Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era”. Arthritis and Rheumatology6 (2017): 1135-1143.
×

Citation

Citation: Mayadhar Barik., et al. “Immunological Aspects of Cytokine Therapy, Signalling Pathway and its Molecular Mechanisms in the Fight Against SARS-CoV-2 ".Acta Scientific Pharmacology 1.10 (2020): 05-18.




Metrics

Acceptance rate36%
Acceptance to publication20-30 days

Indexed In


News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"

Contact US





Creative Commons License Open Access by Acta Scientific is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at https://actascientific.com

ff

Acta-Publications

ff

© 2021 Acta Scientific, All rights reserved.